> top > docs > PubMed:11169513 > annotations

PubMed:11169513 JSONTXT

Annnotations TAB JSON ListView MergeView

c_corpus

Id Subject Object Predicate Lexical cue
T1 30-36 UBERON:0000310 denotes breast
T2 37-51 D063646 denotes carcinogenesis
T3 37-51 D063646 denotes carcinogenesis
T4 122-131 PR:000000230 denotes precursor
T5 122-131 PR:000000291 denotes precursor
T6 275-281 UBERON:0000310 denotes breast
T7 275-288 D001943 denotes breast cancer
T8 275-288 D001943 denotes breast cancer
T9 304-315 D006965 denotes hyperplasia
T10 304-315 D006965 denotes hyperplasia
T13 327-351 D002285 denotes ductal carcinoma in situ
T14 327-351 D002285 denotes ductal carcinoma in situ
T19 353-362 PR:000000230 denotes precursor
T20 353-362 PR:000000291 denotes precursor
T21 479-485 UBERON:0000310 denotes breast
T22 528-534 UBERON:0000479 denotes tissue
T23 568-574 UBERON:0000310 denotes breast
T24 575-581 UBERON:0000479 denotes tissue
T25 602-613 D006965 denotes hyperplasia
T26 602-613 D006965 denotes hyperplasia
T27 629-656 D002285 denotes atypical ductal hyperplasia
T28 629-656 D002285 denotes atypical ductal hyperplasia
T31 658-661 P0A388 denotes ADH
T32 658-661 PR:P06525 denotes ADH
T33 658-661 Q8NXU1 denotes ADH
T34 658-661 Q6GBM4 denotes ADH
T35 658-661 Q47945 denotes ADH
T36 658-661 P0A389 denotes ADH
T37 658-661 Q5HRD6 denotes ADH
T38 658-661 P28036 denotes ADH
T39 658-661 P42327 denotes ADH
T40 658-661 PR:P00332 denotes ADH
T43 658-661 P81786 denotes ADH
T44 658-661 P18278 denotes ADH
T45 658-661 Q44002 denotes ADH
T46 658-661 Q7A742 denotes ADH
T47 658-661 O05542 denotes ADH
T48 658-661 Q2YSX0 denotes ADH
T49 658-661 Q6GJ63 denotes ADH
T50 658-661 PR:P00334 denotes ADH
T52 658-661 Q24857 denotes ADH
T53 658-661 Q8CQ56 denotes ADH
T54 658-661 Q2FJ31 denotes ADH
T55 658-661 Q2G0G1 denotes ADH
T56 658-661 PR:Q2G0G1 denotes ADH
T58 658-661 Q5HI63 denotes ADH
T59 658-661 Q99W07 denotes ADH
T60 658-661 Q04983 denotes ADH
T41 658-661 CHEBI:34543 denotes ADH
T57 658-661 CHEBI:9937 denotes ADH
T42 658-661 GO:0047636 denotes ADH
T51 658-661 GO:0004022 denotes ADH
T63 726-750 D002285 denotes ductal carcinoma in situ
T64 726-750 D002285 denotes ductal carcinoma in situ
T70 752-756 CVCL_5552 denotes DCIS
T69 752-756 D002285 denotes DCIS
T71 752-756 D002285 denotes DCIS
T72 780-786 UBERON:0000310 denotes breast
T73 780-797 D001943 denotes breast carcinomas
T74 780-797 D001943 denotes breast carcinomas
T77 905-911 UBERON:0000310 denotes breast
T78 912-918 UBERON:0000479 denotes tissue
T79 931-940 D002277 denotes carcinoma
T80 931-940 D002277 denotes carcinoma
T81 1045-1051 CHEBI:33252 denotes nuclei
T82 1069-1080 D006965 denotes hyperplasia
T83 1069-1080 D006965 denotes hyperplasia
T84 1172-1183 D006965 denotes hyperplasia
T85 1172-1183 D006965 denotes hyperplasia
T86 1250-1259 PR:000000230 denotes precursor
T87 1250-1259 PR:000000291 denotes precursor
T88 1301-1304 P0A388 denotes ADH
T89 1301-1304 PR:P06525 denotes ADH
T90 1301-1304 Q8NXU1 denotes ADH
T91 1301-1304 Q6GBM4 denotes ADH
T92 1301-1304 Q47945 denotes ADH
T93 1301-1304 P0A389 denotes ADH
T94 1301-1304 Q5HRD6 denotes ADH
T95 1301-1304 P28036 denotes ADH
T96 1301-1304 P42327 denotes ADH
T97 1301-1304 PR:P00332 denotes ADH
T100 1301-1304 P81786 denotes ADH
T101 1301-1304 P18278 denotes ADH
T102 1301-1304 Q44002 denotes ADH
T103 1301-1304 Q7A742 denotes ADH
T104 1301-1304 O05542 denotes ADH
T105 1301-1304 Q2YSX0 denotes ADH
T106 1301-1304 Q6GJ63 denotes ADH
T107 1301-1304 PR:P00334 denotes ADH
T109 1301-1304 Q24857 denotes ADH
T110 1301-1304 Q8CQ56 denotes ADH
T111 1301-1304 Q2FJ31 denotes ADH
T112 1301-1304 Q2G0G1 denotes ADH
T113 1301-1304 PR:Q2G0G1 denotes ADH
T115 1301-1304 Q5HI63 denotes ADH
T116 1301-1304 Q99W07 denotes ADH
T117 1301-1304 Q04983 denotes ADH
T98 1301-1304 CHEBI:34543 denotes ADH
T114 1301-1304 CHEBI:9937 denotes ADH
T99 1301-1304 GO:0047636 denotes ADH
T108 1301-1304 GO:0004022 denotes ADH
T119 1329-1333 CVCL_5552 denotes DCIS
T118 1329-1333 D002285 denotes DCIS
T120 1329-1333 D002285 denotes DCIS
T122 1424-1428 CVCL_5552 denotes DCIS
T121 1424-1428 D002285 denotes DCIS
T123 1424-1428 D002285 denotes DCIS
T124 1493-1502 D002277 denotes carcinoma
T125 1493-1502 D002277 denotes carcinoma
T127 1549-1553 CVCL_5552 denotes DCIS
T126 1549-1553 D002285 denotes DCIS
T128 1549-1553 D002285 denotes DCIS
T129 1618-1624 UBERON:0000310 denotes breast
T130 1618-1631 D001943 denotes breast cancer
T131 1618-1631 D001943 denotes breast cancer
T133 1761-1765 CVCL_5552 denotes DCIS
T132 1761-1765 D002285 denotes DCIS
T134 1761-1765 D002285 denotes DCIS
T136 1854-1858 CVCL_5552 denotes DCIS
T135 1854-1858 D002285 denotes DCIS
T137 1854-1858 D002285 denotes DCIS
T139 1958-1967 GO:0000785 denotes chromatin
T138 1958-1967 D002843 denotes chromatin
T140 2050-2056 UBERON:0000310 denotes breast
T141 2050-2063 D001943 denotes breast cancer
T142 2050-2063 D001943 denotes breast cancer
T143 2120-2147 D002285 denotes atypical ductal hyperplasia
T144 2120-2147 D002285 denotes atypical ductal hyperplasia

UseCases_ArguminSci_Discourse

Id Subject Object Predicate Lexical cue
T1 0-52 DRI_Unspecified denotes Nuclear cytometric changes in breast carcinogenesis.
T2 53-188 DRI_Background denotes Breast cancer is thought to originate through progressively aberrant precursor lesions, paralleled by increasing morphological changes.
T3 189-494 DRI_Background denotes The aim of this study was to quantify nuclear features by image cytometry in invasive breast cancer and its early (hyperplasia) and late (ductal carcinoma in situ) precursor lesions, in order to objectively describe nuclear changes in the spectrum of proliferative intraductal and invasive breast lesions.
T4 495-766 DRI_Background denotes Image cytometry was performed on tissue sections of 20 samples of normal breast tissue, 71 of usual ductal hyperplasia (UDH), nine of atypical ductal hyperplasia (ADH), and 11 of well-differentiated and 13 of poorly differentiated ductal carcinoma in situ (DCIS) lesions.
T5 767-871 DRI_Background denotes The invasive breast carcinomas consisted of 19 well-differentiated and 24 poorly differentiated lesions.
T6 872-1001 DRI_Background denotes Through the spectrum from normal breast tissue to invasive carcinoma, progressive changes in many nuclear features were measured.
T7 1002-1266 DRI_Background denotes Significant differences were found between nuclei of florid ductal hyperplasia compared with mild and moderate ductal hyperplastic lesions, suggesting that florid ductal hyperplasia may be a more advanced lesion than assumed and may contain cancer precursor cells.
T8 1267-1385 DRI_Background denotes No differences were found between ADH and well-differentiated DCIS, suggesting that these lesions are closely related.
T9 1386-1575 DRI_Background denotes Feature values of well-differentiated DCIS were comparable to values found in well-differentiated invasive carcinoma and the same applied to poorly differentiated DCIS and invasive lesions.
T10 1576-1859 DRI_Background denotes These results support the hypothesis that breast cancer develops through different routes of progression, one leading to well-differentiated invasive cancer through well-differentiated DCIS, and one leading to poorly differentiated invasive cancer through poorly differentiated DCIS.
T11 1860-2064 DRI_Background denotes In conclusion, image cytometry reveals progressive changes in nuclear morphological and subvisual chromatin distribution features in the spectrum from intraductal proliferations to invasive breast cancer.
T12 2065-2260 DRI_Outcome denotes This provides evidence for a progression from usual to atypical ductal hyperplasia and then to invasive cancer, through different routes for well-differentiated and poorly differentiated lesions.

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 53-188 DRI_Background denotes Breast cancer is thought to originate through progressively aberrant precursor lesions, paralleled by increasing morphological changes.
T2 189-494 DRI_Background denotes The aim of this study was to quantify nuclear features by image cytometry in invasive breast cancer and its early (hyperplasia) and late (ductal carcinoma in situ) precursor lesions, in order to objectively describe nuclear changes in the spectrum of proliferative intraductal and invasive breast lesions.
T3 495-766 DRI_Background denotes Image cytometry was performed on tissue sections of 20 samples of normal breast tissue, 71 of usual ductal hyperplasia (UDH), nine of atypical ductal hyperplasia (ADH), and 11 of well-differentiated and 13 of poorly differentiated ductal carcinoma in situ (DCIS) lesions.
T4 767-871 DRI_Background denotes The invasive breast carcinomas consisted of 19 well-differentiated and 24 poorly differentiated lesions.
T5 872-1001 DRI_Background denotes Through the spectrum from normal breast tissue to invasive carcinoma, progressive changes in many nuclear features were measured.
T6 1002-1266 DRI_Background denotes Significant differences were found between nuclei of florid ductal hyperplasia compared with mild and moderate ductal hyperplastic lesions, suggesting that florid ductal hyperplasia may be a more advanced lesion than assumed and may contain cancer precursor cells.
T7 1267-1385 DRI_Background denotes No differences were found between ADH and well-differentiated DCIS, suggesting that these lesions are closely related.
T8 1386-1575 DRI_Background denotes Feature values of well-differentiated DCIS were comparable to values found in well-differentiated invasive carcinoma and the same applied to poorly differentiated DCIS and invasive lesions.
T9 1576-1859 DRI_Background denotes These results support the hypothesis that breast cancer develops through different routes of progression, one leading to well-differentiated invasive cancer through well-differentiated DCIS, and one leading to poorly differentiated invasive cancer through poorly differentiated DCIS.
T10 1860-2064 DRI_Background denotes In conclusion, image cytometry reveals progressive changes in nuclear morphological and subvisual chromatin distribution features in the spectrum from intraductal proliferations to invasive breast cancer.
T11 2065-2260 DRI_Outcome denotes This provides evidence for a progression from usual to atypical ductal hyperplasia and then to invasive cancer, through different routes for well-differentiated and poorly differentiated lesions.